Telpoukhovskaia, Maria A.
Liu, Kai
Sayed, Faten A.
Etchegaray, Jon Iker
Xie, Min
Zhan, Lihong
Li, Yaqiao
Zhou, Yungui
Le, David
Bahr, Ben A.
Bogyo, Matthew
Ding, Sheng
Gan, Li
Funding for this research was provided by:
Bluefield Foundation
Coins for Alzheimer’s Research Trust
National Institutes of Health (AG051390)
Article History
Received: 7 January 2020
Accepted: 17 July 2020
First Online: 13 August 2020
Competing interests
: L.G. is a founder of Aeton Therapeutics, Inc. B.A.B is co-inventor on U.S. Patent 8,163,953 and has patent applications pending regarding materials and compound combinations for cathepsin B modulation and methods of use for treating Alzheimer’s disease, mild cognitive impairment, and early dementia. All other authors (M.A.T., K.L, F.A.S, J.I.E, M.X., L.Z, Y.L., Y.Z., D.L., M.B., and S.D.) declare no competing interests.